Miedema, Jelle R.
Moor, Catharina C.
Veltkamp, Marcel
Baart, Sara
Lie, Natascha S. L.
Grutters, Jan C.
Wijsenbeek, Marlies S.
Mostard, Rémy L. M.
Article History
Received: 2 February 2022
Accepted: 18 May 2022
First Online: 28 May 2022
Declarations
:
: Ethics approval was obtained from the Ethical Committee of Erasmus University Medical Centre (MEC-2018-1392). All patients gave written informed consent to participate.
: Not applicable.
: JM reports consulting fees from Boehringer Ingelheim; lecture fees from Boehringer Ingelheim, F. Hoffmann-La Roche, Novartis, outside the submitted work. CM reports grants and fees from Boehringer-Ingelheim and Hoffmann-la Roche, outside the submitted work. All grants and fees were paid to the institution. MV reports consulting fees and lecture honoraria from Boehringer Ingelheim; lecture honoraria from Chiesi; outside the submitted work. MW reports grants from Boehringer Ingelheim, F. Hoffmann-La Roche consulting fees from Boehringer Ingelheim, F. Hoffmann-La Roche, Galapagos, Bristol Myers Squibb, Galecto and Respivant; lecture fees from Boehringer Ingelheim, F. Hoffmann-La Roche, Novartis; travel support from Boehringer Ingelheim, F. Hoffmann-La Roche; and participation in data safety monitoring boards for Savara and Galapagos. All grants and fees were paid to the institution. RM reports consulting fees and lecture honoraria from Boehringer Ingelheim; consulting honoraria from Galapagos; outside the submitted work. All other authors declare that they have no competing interests.